Cross-Sector entity
Of the tracked stories, 3 of 3 also mention Protagonist Therapeutics, the most common co-covered peer. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. The tracked stories average 2 original sources each.
3 verified stories tracked
Last mentioned: Mar 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Protagonist Therapeutics, the most common co-covered peer. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. The tracked stories average 2 original sources each. Verbund appears in 3 tracked Cross-Sector stories from March 17, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Verbund. Shared-story counts are live from our verified record — not editorial picks.
Data Readout
Anticipated top-line data from the Phase 3 VERIFY clinical trial.
Q4 Earnings
Scheduled announcement of quarterly financial results and pipeline update.
Quarterly Earnings Release
Official financial results and conference calls scheduled for both companies.
Pre-Earnings Market Activity
Both OEZVY and PTGX see increased trading volume ahead of Wednesday reports.
Takeda Deal Restructuring
Protagonist opts out of profit-sharing for Rusfertide in exchange for $400M cash.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
VERIFY Enrollment
Completion of enrollment for the Phase 3 trial of rusfertide in polycythemia vera.
J&J Milestone
Protagonist receives $231M milestone payment for icotrokinra progress.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Austrian utility giant Verbund and biotech firm Protagonist Therapeutics are scheduled to release quarterly results this Wednesday. Investors will be scrutinizing Verbund's hydropower margins and Protagonist's cash position following its recent $400 million deal with Takeda.
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Source: themarketsdaily.com · tickerreport.com
